Cardarine (GW-501516): The Endurance Compound
Last updated: October 6, 2026
NOT a SARM — it's a PPARδ agonist. In mice it boosted running time 68% only when combined with exercise training; short human trials showed lipid changes; and serious toxicities in animal studies led GSK to stop development. Here's what the research actually shows.
🧪 Buy Cardarine at Swiss Chems →(Olson 2012 — not a recommendation)
(Mice, Drug + Exercise Training Only)
(Olson 2012, n=268)
Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
Cardarine is NOT a SARM and NOT FDA approved. It's a PPARδ agonist developed for metabolic disorders. GlaxoSmithKline stopped development after serious toxicities were discovered in pre-clinical animal studies (WADA alert (March 2013), as republished by FINA/World Aquatics); GSK withdrew its FDA application in 2009 (GSK statement to The Conversation, 2013). Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013). No safe dose has been established.
All SARMs and this compound are banned by WADA in competitive sport. This page is for educational purposes only.
NOT FDA APPROVED WADA BANNED CANCER CONCERN
How Cardarine Works
Completely different from SARMs. Cardarine activates PPARδ (peroxisome proliferator-activated receptor delta) and is highly selective for it — more than 1,000-fold over the other PPAR subtypes on the human receptor (Oliver et al., Proc Natl Acad Sci USA 2001; PMID 11309497).
Activating PPARδ switches on muscle genes for fatty acid uptake and oxidation. In a 2-week human study, 10 mg/day raised muscle CPT1b expression and the share of meal fat burned for energy (Risérus et al., Diabetes 2008; PMID 18024853).
In sedentary mice, 4 weeks of GW501516 alone changed muscle gene expression but did not improve treadmill endurance. Paired with 4 weeks of exercise training, it increased running time by 68% and distance by 70% versus trained mice given vehicle (Narkar et al., Cell 2008; PMID 18674809). The AMPK activator AICAR, not GW501516, was the drug that raised endurance without exercise in that study. Mice engineered to express an activated form of PPARδ in muscle had more type I (oxidative) fibers and ran much farther (Wang et al., PLoS Biol 2004; PMID 15328533).
In a 12-week trial of 268 people with low HDL, 2.5–10 mg/day raised HDL cholesterol by up to 16.9% and lowered LDL cholesterol (by up to 7.3%) and triglycerides (by up to 16.9%) (Olson et al., Arterioscler Thromb Vasc Biol 2012; PMID 22814748). In a 2-week study in 6 moderately overweight men, 10 mg/day lowered triglycerides 30% and LDL 23%, with HDL unchanged (Risérus et al., Diabetes 2008; PMID 18024853). It was developed for dyslipidemia and metabolic syndrome.
GSK stopped development after serious toxicities appeared in pre-clinical studies (WADA alert (March 2013), as republished by FINA/World Aquatics). Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013). The published human trials lasted 2–12 weeks and were not designed to detect cancer risk; there is no long-term human safety data.
What the Research Shows
Data context: The endurance data come from mice. The human data are small lipid trials lasting 2–12 weeks at 2.5–10 mg/day; they were not designed to detect cancer risk. Serious toxicities in animal studies ended the program.
Side Effects & Risks
- Serious toxicities in pre-clinical studies ended development
- Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013)
- No safe dose established
- Human trials lasted only 2–12 weeks — too short to assess cancer risk
- Unknown risk in people
- Published human trials were small and short
- Black-market products are unregulated
Study Citations
Key Takeaways
- NOT a SARM — PPARδ agonist with different mechanism
- In mice, endurance rose 68% only with exercise training — not from the drug alone
- Raised HDL and lowered triglycerides/LDL in 2–12 week human trials
- GSK stopped development after serious pre-clinical toxicities
- Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013)
- WADA banned in sport
- Cancer risk at human research doses
- Long-term human safety data
- Quality of research chemical supply
- Whether it improves endurance in humans at all
- Interaction with other compounds
Research Source
Swiss Chems is our affiliate vendor for research compounds.
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Educational purposes only. Not medical advice. Cardarine is NOT FDA approved. GSK stopped development after serious toxicities in pre-clinical studies. Banned by WADA. Consult healthcare provider. HighPeptides does not sell this compound.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.